PPMI Completed & Ongoing Biologic Analyses
Principal InvestigatorOrganizationProject TitleData AvailabilityAnalyteMatrixIncluded Enrollment CohortsSubcategories includedVisit(s)Project IDNotes
 Collaboration powered by Smartsheet   |   Report Abuse
1Andrew Singleton, PhDNIAAPOE4 Genotyping​Currently available
APOE4 genotyping​
DNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
N/ABaseline104
2Clemens Scherzer, MDHarvardEvaluation of PD-linked Transcripts in PPMICurrently available
aSyn transcripts
RNA from whole bloodHealthy Control
Parkinson Disease
N/ABaseline105
3Andrew Singleton, PhDNIAImmunochip Genotyping on DNA Samples from PPMICurrently available
Immunochip genotyping​
DNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
N/ABaseline108
4Alice Chen-Plotkin, MD, MScUPennPlasma Apolipoprotein A1 Level as a Biomarker in Parkinson’s DiseaseCurrently available
ApoA1 & EGF​
PlasmaHealthy Control
Parkinson Disease
N/ABaseline, 6, 12 months112
5Maria Teresa Pellecchia, PhDUniversity of SalernoInsulin-like Growth Factor-1 as a Biomarker of Early Cognitive Impairment in PDCurrently available
IGF-1
SerumHealthy Control
Parkinson Disease
N/ABaseline113
6Judith Potashkin, PhDRosalind & Franklin UniversityWhole blood RNA Biomarkers of PDCurrently available
mRNA transcripts
RNA from whole bloodHealthy Control
Parkinson Disease
N/ABaseline114
7Matthew Farrer, PhDUniversity of BCClinical, Imaging, & Plasma & CSF Correlates of aSyn Genomic VariabilityCurrently available
SNCA genotyping​
DNA from whole bloodHealthy Control
Parkinson Disease
N/ABaseline115
8Andrew Singleton, PhDNIAExome Sequencing of PPMI samplesCurrently available
Whole exome sequencing
DNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
N/ABaseline116
9Andrew Singleton, PhDNIAWhole Genome Sequencing & Analysis of PPMI Prodromal & Genetic Cohorts & Genetic Registry​Currently available
Whole genome sequencing
DNA from whole bloodHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline118
10Martin Rabey, MDBioShai Ltd.Validation of a blood-based Gene Expression Assay for Early Diagnosis & Monitoring DiseaseCurrently available
mRNA transcripts
RNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
N/ABaseline, 12, 24, 36 months119
11Dena Hernandez, PhDNIA​DNA Methylation in PPMICurrently available
Dna methylation
DNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
N/ABaseline120
12Thomas Kremer, PhD; Kristen Taylor, PhDRocheCSF Neurotransmitter Metabolites as Promising Diagnostic & Disease Severity Biomarkers in Early-Stage PD Patients​Currently available
Catecholamines​
CSFHealthy Control
Parkinson Disease
N/ABaseline, 12, 24 months122
13Dwight German, PhDUT SouthwesternBlood Biomarker for PDCurrently available
PD2 peptoid
SerumHealthy Control
Parkinson Disease
N/ABaseline123
14Peggy Taylor, PhDBioLegendaSyn Measurements in Longitudinal CSF Samples From De Novo, PD, CT, SWEDD, Prodromal, & Genetic Cohorts​Currently available
total aSyn, hemoglobin, & total protein
CSFHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline, 6, 12, 24, 36 months124PD, HC, SWEDD through yr 3, prodromal & genetic through yr 1
15Andrew Singleton, PhDNIAGBA SequencingCurrently available
GBA sequencing
DNA from whole bloodHealthy Control
Parkinson Disease
SWEDD (legacy)
N/ABaseline126
16Satpal Virdee, PhD,University of Dundee​Profiling PINK1-Parkin Functionality in Patient Fibroblasts Using Chemical ProbesCurrently available
PINK1
FibroblastsHealthy Control
Parkinson Disease
N/AN/A127
17Xinnan Wang, PhDStanford University​Miro, a Biomarker for Parkinson’s DiseaseCurrently available
Miro
Fibroblasts
iPSCs
Healthy Control
Parkinson Disease
Prodromal
Genetic subjectsN/A129
18Gavin Hudson, PhDNewcastle UniversityThe Role of Cell-Free Mitochondrial DNA in Neurodegenerative DiseaseCurrently available
Cell-free mitochondrial Dna
CSFHealthy Control
Parkinson Disease
N/ABaseline, 36 months130
19Nilima Prakash, PhDHamm-Lippstadt University of Applied Sciences​Altered Calcium Activity Patterns in Developing Dopaminergic Neurons from PD Patients as an Early Indicator of Disease Predisposition or ProgressionCurrently available
Calcium activity
Fibroblasts
iPSCs
Healthy Control
Parkinson Disease
N/AN/A136
20Rachit Bakshi, PhDMGH/MIND​Urate & Nrf2 Pathway Effects on Mutant LRRK2 Toxicity in iPSC-Derived DA NeuronsCurrently available
Urate & Nrf2​
iPSCsHealthy Control
Parkinson Disease
Prodromal
LRRK2 subjectsN/A137
21Mark Cookson, PhD​NIALRRK2 Genetic Risk Variants in PDExpected Q2 2024
LRRK2 functional variants​
iPSCsHealthy Control
Parkinson Disease
Prodromal
Genetic subjectsN/A139
22Travis Dunckley, PhD; Paula Desplats, PhDArizoN/A State University; UCSDComprehensive Methylation Profiling of the PPMI Cohort​Currently available
Methylation profiling​
DNA from whole bloodHealthy Control
Parkinson Disease
Prodromal
LRRK2 subjectsBaseline, 12, 24, 36 months140
23Nic Dzamko, PhDUniversity of Sydney​Inflammatory phenotypes in differentiated human LRRK2 & GBA mutation IPS cell linesCurrently available
Inflammation/​lysosomal function
iPSCsHealthy Control
Parkinson Disease
Prodromal
GBA & LRRK2 subjectsN/A141
24Danielle Graham, PhD; Brit Mollenhauer, MDBiogen; Paracelsus EleN/A KlinikInvestigation of Neurofilament Light Chain in Serum from the PPMI Cohorts as Progression Marker for PD​Currently available
Neurofilament Light (NFL)​
SerumHealthy Control
Parkinson Disease
Prodromal
Genetic subjectsPD & HC: Baseline, 6, 12, 24, 36, 60 months; Prodromal & genetic cohorts: Baseline, 6, 12, 24, 36 months144
25Kalpana Merchant, PhDTransTheraDo Urinary BMP Levels Change with Disease Progression in Idiopathic & Genetic PD?Currently available
BMP
UrineHealthy Control
Parkinson Disease
Prodromal
GBA & LRRK2 subjectsPD, HC, & GBA: Baseline only; LRRK2: Baseline, 12, 24 months145
26Dimitri Krainc, MDNorthwestern UniversityConvergence of LRRK2 & GBA1 in the Pathogenesis of Parkinson’s DiseaseCurrently available
GCase activity in dopaminergic neurons​
iPSCsHealthy Control
Parkinson Disease
LRRK2 subjectsN/A148
27Matt LaVoie, PhDBrigham & Women’s, Harvard​Role of LRRK2 in Gcase-mediated Alterations in Lysosome Functions & aSyn MetabolismCurrently available
LRRK2 at lysosomes
iPSCsParkinson DiseaseGBA subjectsN/A149
28Andy Singleton, PhDNIAThe Foundational Data InitiativeCurrently available
Transcriptional activity, gene regulation, epigenetics​
iPSCsHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsN/A150Data portal under development
29Fiona Elwood, PhDNovartisIdentification of Proteins & Protein Networks in Human CSF That Differentiate Within PD Patients​Currently available
SomaLogic collaboration (with Merck & Novartis)​
CSFHealthy Control
Parkinson Disease
Prodromal
Genetic subjectsBaseline151
30Richard Batrla-Utermann, PhDRocheRoche NeuroTool KitCurrently available
Roche Elecsys NeuroTool Kit (aSyn, GFAP, IL-6, S100b, neurogranin, NFL, sTREM2, YKL40)​
CSFHealthy Control
Parkinson Disease
N/ABaseline, 6, 12, 24, 36, 48 months152
31Thomas Schwarz, PhDBoston Children’s Hospital​Mitochondrial Transport Defects as a Potential Biomarker in Patient-derived CellsCurrently available
Mitochondrial transport​
iPSCsHealthy Control
Parkinson Disease
Genetic subjectsN/A153
32Ellen Sidransky, MD​NIHDevelopment of Novel TRPML1 Activator for Treatment of PDData unavailable
Calcium channel agonists
iPSCsHealthy Control
Parkinson Disease
N/AN/A154
33Claudio Soto, PhDAmprionMonitoring the Progression & Pre-clinical Diagnosis of PD by Detection of aSyn Oligomers in CSF Using the PMCA AssayCurrently available
aSyn seeding (PMCA)- Round Robin & Phase 2​
CSFHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsPhase 1: Baseline, 36, mo; Phase 2: PD, HC, SWEDD at Baseline, prodromals at all visits, SNCA at all visits, LRRK2/GBA PD at Baseline and NMC at Baseline & all visits for phenoconverted155Phase 1 (bl & 36 months) PD, CT, SWEDD currently available; remaining data expected EOY
34Aaron Day WilliamsFlagship 60​Investigation of Phenotypic Differences Between Familial PD, Idiopathic PD and Controls in Patient-derived iPSCsCurrently available
Phenotyping
iPSCsHealthy Control
Parkinson Disease
Prodromal
LRRK2 subjectsN/A156
35Marlene Jacobson, PhDUniversity of Dundee​Investigating the Effect of Small Molecules to Rescue Lysosomal & GBA-1 Deficiencies in GBA-PDCurrently available
Lysosomal rescue​
FibroblastsHealthy Control
Parkinson Disease
N/AN/A158
36Les Shaw, PhDUPennPPMI CSF A-beta42, t-tau, and p-tau 181 Analysis 2019Currently available
Aβ, tau, & p-tau181 ​
CSFHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline, 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 months15975 Bridging study & 2,000+ remaining PPMI samples not yet aN/Alyzed from previous efforts
37Sulev Koks, MD, PhDMurdoch UniversityAssociation of Repetitive Elements with Parkinson's Disease Risk and Progression in the PPMI CohortCurrently available
Tandem repeats
DNA from whole bloodHealthy Control
Parkinson Disease
N/ABaseline160
38Maximiliano Gutierrez, PhDFrancis Crick Institute​The Role of LRRK2 Kinase Activity in Human Macrophage FunctionCurrently available
LRRK2 kinase activity
iPSCsParkinson DiseaseLRRK2 subjectsN/A161
39Liana Rosenthal, MDJohn HopkinsIs Poly ADP-ribose in the CSF a Biomarker for PD Diagnosis or Progression?​Currently available
Poly ADP-ribose​
CSFHealthy Control
Parkinson Disease
N/ABaseline, 6, 12, 18, 24, 36,48, 60 months165
40Eleanor Coffey, PhDTurku Centre for Biotechnology​PD Signature Validation Project Related to "Improving Patient Diagnosis, Stratification & Disease Monitoring in PDExpected Q3 2024
Protein handling
PBMCsHealthy Control
Parkinson Disease
Prodromal
Genetic subjects3 longitudinal timepoints170
41Cornelis Blauwendraat, PhDNIALong read DNA sequencing of the PPMI cohort​Expected Q2 2024
Long read Dna sequencing​
DNA from whole bloodHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline171
42Byron Caughey, PhDNIHaSyn Seeding Assay Round Robin- NIH​Currently available
aSyn seeding​ (RT-QuIC)- Round Robin
CSFHealthy Control
Parkinson Disease
SWEDD (legacy)
N/ABaseline, 36 months172
43Roland Heym, PhDAbbvieEvaluation of Seeding-competent aSyn in the CSF as a Biomarker for Parkinson’s DiseaseCurrently available
aSyn seeding​ (RT-QuIC)- Round Robin
CSFHealthy Control
Parkinson Disease
SWEDD (legacy)
N/ABaseline, 36 months173
44Dong-Gyu Jo, PhDSungkyunkwan University​Study for the Propagation of aSyn (Screening the Propagation Relative Genes)Expected Q4 2024
aSyn propagation
iPSCsHealthy Control
Parkinson Disease
GBA & LRRK2 subjectsN/A174
45Kirsten Taylor, PhDRocheaSyn PMCA Assay at AmprionCurrently available
aSyn seeding​ (PMCA in leftover samples)
CSFHealthy Control
Parkinson Disease
N/ABaseline, 12, 24 months176
46Jennifer Van Eyk, PhDCedars-SinaiPost-Translational Modification & Protein Quantification of Plasma & CSFCurrently available
Unbiased proteomics (DIA MS, AMP PD)
CSF
Plasma
Healthy Control
Parkinson Disease
N/ABaseline & 3 longitudinal timepoints177
47Kimberly Billingsley, PhDNIHIdentifying the Role of Structural Variants in PDExpected Q3 2024
Structural variants
DNA from whole bloodHealthy Control
Parkinson Disease
N/AVarious179
48Michael Schwarzschild, PhDMGH & DenaliMetabolomic Analysis of Penetrance, Prognosis, & Tracking Biomarkers of LRRK2 PDPlasma available; CSF Expected Q2 2024
Metabolomics
CSF
Plasma
Healthy Control
Parkinson Disease
Prodromal
GBA & LRRK2 subjectsPlasma: Baseline,12, 24 months; CSF: Baseline only180, 215
49Marion Buckwalter, PhDStanfordAdaptive Immune Markers for Predicting Cognitive Decline in PDCurrently available
Immune profiling
CSF
Plasma
Healthy Control
Parkinson Disease
N/ABaseline, 48 months181
50Shawn Ritchie, PhDMed-Life DiscoveriesValidation of Plasmalogen Augmentation as a Viable Drug Target in PD​Currently available
Plasmalogen​
PlasmaHealthy Control
Parkinson Disease
SWEDD (legacy)
Genetic subjectsBaseline182
51Deniz KirikUniversity of SydneyAn in vivo approach to elucidate the pathobiology of PD-associated genes using human diseased neuronsExpected Q3 2024
Whole genome sequencing on midbrain and cortical neurons and astrocytes
Fibroblasts
iPSCs
Healthy Control
Parkinson Disease
N/AN/A193
52Alejandro Pezzulo, MDUniversity of IowaMultidisciplinary Analysis of Metabolic Dysregulation in Parkinson's DiseaseExpected Q2 2024
Metabolic profiling
FibroblastsHealthy Control
Parkinson Disease
N/AN/A194
53Christos Proukakis, MD, PhDUniversity College LondonDetection of GBA Mutations by Combination of Illumina & nanopore Sequencing​Currently available
Long read GBA sequencing
DNA from whole bloodParkinson Disease
Prodromal
GBA subjectsVarious195
54Eline Appelmans, PhDFNIHTargeted Proteomics in AMP PDCurrently available
Targeted proteomics (O-Link Explore 1536, AMP PD)​
CSF
Plasma
Healthy Control
Parkinson Disease
N/ABaseline & 3 longitudinal timepoints196
55Xiqun Chen, MD, PhDMass General Hospital​From Cancer Associations to Altered Immunity in the Pathogenesis of Parkinson’s DiseaseExpected Q2 2024
Inflammation
iPSCsHealthy Control
Parkinson Disease
LRRK2 subjectsN/A197
56Erika Holzbaur, PhDUPenn​Investigating Mitochondrial Trafficking Deficits Across PD ModelsExpected Q3 2024
Mitochondrial trafficking​
iPSCsHealthy ControlGenetic subjectsN/A198
57Magdalene Moran, PhDCaraway Therapeutics​Developing TMEM175 Activators as Therapeutics for PDCurrently available
TMEM175 activators​
iPSCsParkinson DiseaseGBA subjectsN/A199
58Adam Mamais, PhDUniversity of Florida​Converging Pathways of LRRK2 & PINK1 Biology Impacting Iron Homeostasis & Mitochondrial FunctionCurrently available
Iron & mitochondrial homeostasis​
iPSCsHealthy Control
Parkinson Disease
LRRK2 subjectsN/A202
59Massimiliano BianchiUlysses Neuroscience LtdValidation of microtubule dynamics as a novel target in Parkinson’s diseaseExpected Q2 2024
Microtubule dynamics in midbrain-like 3D organoid cultures
iPSCsHealthy Control
Parkinson Disease
Prodromal
iPD, HyposmicN/A203
60George Tofaris, MD, PhDUniversity of OxfordSerum Neuronal Exosomes as Predictive or Dynamic Biomarkers in PDPartially available
Neuronal exosomes (aSyn)​
SerumHealthy Control
Parkinson Disease
Prodromal
GBA, LRRK2, RBD, HyposmicBaseline, 3, 6 Months204
61Kiroaki Kaku, PhDWestern Michigan University​The Role of FAIM in Parkinson’s Disease​Expected Q2 2024
FAIM
iPSCsParkinson DiseaseGBA & SNCA subjectsN/A206
62Karen MacLeod, Claudio Soto, PhDAmprionDevelopment and Optimization of Semi-Quantitate PMCA for Analysis of Soluble ASYN Aggregates in CSF in Amprion's Clinical LaboratoryCurrently available
aSyn seeding (PMCA)
CSFHealthy Control
Parkinson Disease
N/AVarious207Used warmed CSF from various visits
63ZinnhardtRocheIdentification of NLRP3 Inflammasome-related biomarkers in PPMI CSF SamplesCurrently available
IL1B
CSFHealthy Control
Parkinson Disease
N/ABaseline, 12, 24 Months209
64Anumantha Kanthasamy, PhDIowa State UniversityPPMI a-Syn Skin Seeding AssayCurrently available
aSyn seeding​ (RT-QuIC)- Round Robin
SkinHealthy Control
Parkinson Disease
N/ABaseline211
65Bahareh Ajami, Dario AlessiOregon Health & Science University, University of DundeeInvestigating the influence of genetic risk factors of PD on peripheral immune cells to identify potential biomarkers for prediction of conversion of non-manifesting to manifesting carriers.Partially available
Immune Cell Phenotyping, transcriptomics and proteomics”
PBMCs
Plasma
Parkinson DiseaseN/AN/A213
66Khalil RamadiNew York UniversityNeural Chemical Delivery System for Treatment of Parkinson's DiseaseExpected Q3 2024
Dopamine neuronal cell survival, engraftment, and integration
Fibroblasts
iPSCs
Healthy Control
Parkinson Disease
N/AN/A216
67Julian Peter SefrinAbbvieEvaluation of TMPRSS5 (Spinesin) in the CSF as a potential biomarker for early Parkinson’s disease diagnosis and progressionCurrently available
Spinesin
CSFParkinson Disease
Prodromal
Phenoconverters, Short Duration iPD, Genetic Subjects, Hyposmic, RBDBaseline, 6, 12, 24, 36, 48, 60 Months219
68Omar MabroukBiogenCSF total LRRK2 measurements as a Biomarker in genetic PDPartially Available
LRRK2
CSFHealthy Control
Parkinson Disease
Prodromal
GBA & LRRK2 subjectsBaseline, 24 Months221
69Anthony SchapiraUCL Medical SchoolThe genome-microbiome axis in the cause of Parkinson disease: Mechanistic insights and therapeutic implications from experimental models and a genetically stratified patient populationExpected Q2 2024
Assessing PD phenotypes in enteric neurons, dopaminergic neurons, astrocytes, microglia
iPSCsHealthy Control
Parkinson Disease
N/AN/A223
70Céline GalvagnionUniversity of CopenhagenUnderstanding selective neuronal vulnerability in the context of Parkinson's DiseaseExpected Q3 2024
Proteomics and lipidomics in dopamine and cortical neurons
iPSCsHealthy Control
Parkinson Disease
LRRK2, iPDN/A224
71Susanna NarkilahtiUniversity of TampereElectrophysiological Phenotype Characterization of iPSC-derived Neuronal Cells with PD-linked LRRK2 Mutations during Network Formation and Alpha-Synuclein Seeded AggregationExpected Q1 2025
electrophysiological phenotype
iPSCsHealthy Control
Parkinson Disease
Prodromal
LRRK2 G2019S, LRRK2 R1441GN/A227
72Mark Cookson, PhDNIHFOUNDIN[mu]- a microglial resource for PPMI linesExpected Q1 2025
ATACseq and RNAseq in microglia
iPSCsHealthy Control
Parkinson Disease
N/AN/A228
73Sonia GandhiUniversity College LondonDefining mechanisms in neurons and oligodendrocytes that drive progression in Parkinson’sExpected Q4 2024
High content imaging, transcriptomics in dopamine neurons and oligodendrocytes
iPSCsHealthy Control
Parkinson Disease
Prodromal
iPD, SNCA (A53T), Hyposmic, RBDN/A229
74Rhalena ThomasMcGill UniversityA pipeline for massive multiplexing of iPSC-derived dopaminergic neurons and microglia for cohort-scale transcriptomics in PDExpected Q4 2024
scRNAseq profiling of pooled iPSC dervied neurons and microglia
iPSCsHealthy Control
Parkinson Disease
Prodromal
iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), HyposmicN/A230
75Lezanne OoiUniversity of WollongongMetabolic phenotyping in PD dopaminergic neurons and neuronal-glial co-cultures using high-throughput single-cell metabolomics and lipidomicsExpected Q2 2024
Single cell metabolomics and lipidomics in dopamine neurons, Astrocytes, Microglia
iPSCsHealthy Control
Parkinson Disease
Prodromal
iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), HyposmicN/A231
76Gist CroftThe New York Stem Cell FoundationA cohort-wide resource of transcriptomic and morphological phenotypes in defined neural cell typesExpected Q2 2024
RNAseq and cell painting in NGN2 neurons and cortical excitatory neurons
iPSCsHealthy Control
Parkinson Disease
Prodromal
iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), Hyposmic, RBDN/A232
77Yuriy PomeshchikLund UniversityUncovering proteomic alterations in Parkinson’s disease using patient-specific iPSC-derived brain cellsExpected Q2 2024
Proteomics in neurons, astrocytes and oligodendrocytes
iPSCsHealthy Control
Parkinson Disease
Prodromal
iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), HyposmicN/A233
78Laurent RoybonVARIOmic-based analyses of PD iPSC-derived brain cellsExpected Q3 2024
Multi-omics characterization of diverse cell types (DA neurons & cortical neurons, astrocytes, oligodendrocyte, and microglia)
iPSCsHealthy Control
Parkinson Disease
Prodromal
iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), HyposmicN/A234
79Lalitha MadhavanUniversity of ArizonaDeep phenotyping of PD relevant mitochondrial and autophagic mechanisms in human iPSC-derived neural cellsExpected Q4 2024
mitochondrial and autophagic phenotypes/alpha-synuclein
iPSCsHealthy Control
Parkinson Disease
iPD, HCN/A235
80Souvik ModiESYA LabsESYA PD360: A multi-parametric platform for establishing a novel lysosome-based biomarker and identifying therapeutic interventions for Parkinson’s DiseaseExpected Q2 2024
RNAseq, pH, calcium and autophagy analyses in fibroblasts
FibroblastsHealthy Control
Parkinson Disease
iPDN/A236
81Luis Concha, PhDAmprionAnalysis of CSF samplesOngoing availability
Alpha-Synuclein Seeds
CSFHealthy Control
Parkinson Disease
Prodromal
N/ABaseline, 6, 12 Months237
82Daniel YsselsteinVanqua BioGlucocerebrosidase Activation as a Therapeutic Strategy for Parkinson’s DiseaseExpected Q1 2025
Longitudinal assessment of GCase activity, insoluble aSyn, sphingolipids, and lysosomal dysfunction in DA neurons
iPSCsHealthy Control
Parkinson Disease
GBA, iPDN/A239
83Nick Hertz, PhDMitokininAssessing pS65 Ubiquitin levels in biofluids as a biomarker for Parkinson's DiseaseCurrently available
pS65Ub
CSF
Plasma
Healthy Control
Parkinson Disease
Prodromal
N/ABaseline, 6, 12, 24, 36, 48, 60 months240
84Hilde NilsenOslo University HospitalMitochondrial Transcription regulation via Base Excision RepairExpected Q1 2025
NTHL1
iPSCsHealthy Control
Parkinson Disease
Prodromal
SNCAN/A241
85Ivan Martinez-ValbuenaUniversity of TorontoDeveloping a standardized skin-based alpha-synuclein seeding amplification assay for the diagnosis of Parkinson’s diseaseExpected Q3 2024
SAA
TissueHealthy Control
Parkinson Disease
N/ABL, 6, 48,248
86Joanne TrinhInstitute of Neurogenetics, LuebeckInteraction of the environment and somatic modifiers in mitochondrial genes on disease penetranceExpected Q3 2027
mitochondrial DNA variations
DNA from whole bloodHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
N/ASC and Baseline250
87Andrew Singleton, PhDNIASelected Genetic Variants Genotyped Using NeuroX ArrayCurrently available
NeuroX genotyping
DNA from whole bloodHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline106, 107
88Les Shaw, PhDUPennA-beta 1-42, t-tau and p-tau 181 Measurements in PPMI CSF Samples using xMAP/Luminex Multiplex Immunoassay & Roche ElecsysCurrently available
Aβ, tau, & p-tau181 ​
CSFHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaseline, 6, 12, 24, 36 months110, 125Innogentics: PD, HC, & SWEDD through yr 1; Elecsys: PD, HC, & SWEDD through yr 3, prodromal & genetic through yr 1
89Kendall Van Keuren-Jensen, PhDTGen FoundationRNAseq in PPMICurrently available (summary files, raw data for cloud transfer, & data explorer)​
mRNA& miRNA sequencing​
RNA from whole bloodHealthy Control
Parkinson Disease
Prodromal
SWEDD (legacy)
Genetic subjectsBaselilne, 6, 12, 24, 36 months131, 133Data available as summary files, raw data for cloud transfer, & data explorer
90Pablo Sardi, PhDSanofiGBA-Related Biomarkers in Parkinson's DiseaseCurrently available
GCase activity & sphingolipids​
CSF
Plasma
Whole blood
Healthy Control
Parkinson Disease
SWEDD (legacy)
N/ABaseline, 12, 24, 36 months132, 135
91Sebastian Virreira Winter, PhDOmicEra​Targeted & Untargeted MS Based Proteomics of Urine in PDCurrently available
Urine proteomics
UrineHealthy Control
Parkinson Disease
Prodromal
GBA & LRRK2 subjectsPD, HC, & GBA: Baseline only; LRRK2: Baseline, 12, 24 months190
92Maximilliano Gutierrez, PhDThe Francis Crick InstituteThe impact of the LRRK2 G2019S mutation on lysosomal function in macrophagesExpected Q1 2026
LRRK2 kinase activity
iPSCsParkinson DiseaseN/AN/A254
93Nobutaka HattoriJuntendoValidation of a Serum Synuclein Seed Amplification Assay IP/SAA in PPMIExpected Q2 2024
SAA
SerumParkinson DiseaseN/ABaseline, 6, 12 Months249
94Sarah Huntwork-RodriguezDenaliMetabolomic Analysis of Penetrance, Prognosis and Tracking Biomarkers of LRRK2 PDExpected Q4 2024
Polyanmines
CSF
Plasma
Healthy Control
Parkinson Disease
Prodromal
GBA & LRRK2 subjectsPlasma: Baseline,12, 24 months; CSF: Baseline only261
95Michael SchwarzchildMassachusetts General HospitalMetabolomic Analysis of Penetrance, Prognosis and Tracking Biomarkers of LRRK2 PDExpected Q2 2024
B12
CSF
Plasma
Healthy Control
Parkinson Disease
Prodromal
GBA & LRRK2 subjectsPlasma: Baseline,12, 24 months; CSF: Baseline only243
96Aparna VasanthakumarAbbvieO-Link in PPMICurrently Available
Targeted proteomics
CSF
Plasma
Baseline, 6, 12, 24, 36, 48, 60 months222
97Dave SulzerResearch Foundation for Mental Hygiene, Inc.Adaptive immunity in the etiology and progression of Parkinson’s diseaseCurrently available
aSyn-reactive T cells
PBMCsHealthy Control
Parkinson Disease
Prodromal
245